This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy
of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal
response in participants with active lupus nephritis (LN).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)